Supply Chain Research

The administration of President Donald Trump may be willing to drop proposals related to standardized biologic drug patent lengths in order to secure passage of the U.S.-Mexico-Canada Agreement, USMCA, through the U.S. House of Representatives. Setting patent protections to 10 years across the region – currently the U.S. has 12 years of protections versus eight and five in Canada and Mexico – has been one of four demands from House Democrats. The move is unlikely to be popular with the pharmaceutical industry, but could help boost demand for Mexican drug imports from the U.S. Imports of ...